iRadimed Corporation (NASDAQ:IRMD) Receives Average Recommendation of “Buy” from Brokerages

Shares of iRadimed Corporation (NASDAQ:IRMD) have been given a consensus recommendation of “Buy” by the five ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $120.00.

Several brokerages have recently weighed in on IRMD. Lake Street Capital reiterated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a report on Wednesday, February 11th. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Freedom Capital raised iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Finally, Roth Mkm reiterated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th.

Insider Activity

In related news, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction on Monday, March 9th. The shares were sold at an average price of $100.04, for a total value of $500,200.00. Following the completion of the sale, the chief executive officer owned 2,250,000 shares of the company’s stock, valued at approximately $225,090,000. This trade represents a 0.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 37,500 shares of company stock valued at $3,765,750. 36.80% of the stock is owned by company insiders.

Institutional Trading of iRadimed

Several hedge funds have recently bought and sold shares of the business. CWM LLC raised its stake in shares of iRadimed by 19.5% in the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after buying an additional 107 shares during the period. Johnson Investment Counsel Inc. boosted its holdings in shares of iRadimed by 0.7% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock worth $1,839,000 after purchasing an additional 187 shares in the last quarter. Summit Global Investments boosted its holdings in shares of iRadimed by 2.7% in the 3rd quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock worth $508,000 after purchasing an additional 188 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 234 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of iRadimed by 4.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock worth $567,000 after purchasing an additional 267 shares in the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Stock Performance

iRadimed stock opened at $95.66 on Tuesday. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of 54.66 and a beta of 1.11. iRadimed has a 52-week low of $47.48 and a 52-week high of $107.90. The stock’s 50 day moving average price is $99.63 and its two-hundred day moving average price is $91.74.

iRadimed (NASDAQ:IRMD) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.05. The company had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, equities research analysts forecast that iRadimed will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Monday, February 23rd. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. iRadimed’s payout ratio is currently 45.71%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.